Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03152448 · ClinicalTrials.gov registry record
Prospective Prolaris Value and Efficacy
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 1,511
- Enrollment target
NCT03152448: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT03152448 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 1,511 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03152448 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 1,511 participants
- Enrollment target
Study Summary
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
Interventions
- BEHAVIORAL Prolaris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,511 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2022-03-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03152448
The ClinicalTrials.gov registry entry for NCT03152448 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1,511 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Prolaris is the first listed.
NCT03152448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03152448 about?
NCT03152448 is a clinical study titled "Prospective Prolaris Value and Efficacy". This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
What is the current status of trial NCT03152448?
This trial is currently terminated. The enrollment target is 1,511 participants. The study started on 2015-09-01. Estimated completion is 2022-03-21.
What interventions are being tested in trial NCT03152448?
The interventions under investigation include: Prolaris (BEHAVIORAL).
Who is sponsoring clinical trial NCT03152448?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.